Agilent Technologies acquires manufacturer of synthetic nucleic acids for pharmaceutical and biotech industries
Acquisition addresses rapidly growing RNA synthesis market
Agilent Technologies Inc. announced that it has acquired privately held SynPro Corp., the owner of a contract manufacturing facility established to supply active pharmaceutical ingredients and provide related services. Financial details were not disclosed.
Based in Boulder, Colo., the facility manufactures short synthetic DNA and RNA molecules that are becoming more important to the pharmaceutical and biotech industries as components of drugs for use in clinical trials. Emerging biopharmaceutical companies engaged in drug development will increasingly need to rely upon the technical expertise and operating sophistication of their vendors for successful commercialization of complex components. The acquisition will enable Agilent to offer an array of value-added services, including development of analytical methods and processes, stability studies, quality control, and regulatory support.
"Agilent has identified RNA synthesis as an excellent growth opportunity," said John Eaton, Agilent vice president, Corporate Development. "Acquiring SynPro is a strategic move for us. We are gaining first-rate manufacturing capabilities and deep expertise that will open the door for Agilent to an exciting new market."
Other news from the department business & finance
